Zhang 2008b.

Methods	Allocation: randomised, no further details. Blindness: unclear. Duration: six weeks. Design: parallel. Location: inpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). N = 40. Age: aripiprazole group: 18‐58 years, mean = (33.2 ± 7.8) years; risperidone group: 18‐65 years, mean = (34.5 ± 8.7) years. Gender: aripiprazole group: 8 Male, 12 Female; risperidone group: 10 Male, 10 Female . History: aripiprazole group: 1 month‐5 years, mean = (2.8 ± 3.6) years; risperidone group: 2 months‐7 years, mean = (3.7 ± 4.2) years. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 5‐30 mg/day. Mean = (10 ± 5.22) mg/day. N = 20. 2. Risperidone: Dose range: 1‐6 mg/day. Mean = (3.5 ± 0.8) mg/day. N = 20
Outcomes	Global state: PANSS score decreased rate (recovery: ≥ 75%, markedly improved: 50%‐75%, improved: 20%‐50%, no effect: < 25%). Mental state: PANSS total score, PANSS positive subscale score, PANSS negative subscale score, PANSS general psychogenic pathological subscale score. Adverse effects. Unable to use ‐ Adverse effects: TESS total score, endocrine change, laboratory tests (no data).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data.
Selective reporting (reporting bias)	High risk	Data on TESS score, endocrine change, laboratory tests were missing. No data of Quality of life GQOLI ‐ 74.
Other bias	Low risk	None obvious.